Hot Topics on CAR T- Cell Therapy from the 63rd ASH Annual Meeting*

Certified AMA Activity - Clinical Clips

The introduction of chimeric antigen receptor (CAR) T-cell therapies has shifted the paradigm for several incurable and refractory hematologic malignancies and currently various cellular immunotherapies are under investigation. To ensure updated ongoing care for patients, clinicians need to be familiar with recent clinical trial evidence on approved and emerging CAR T-cell therapies.

This educational Clinical Clip focused on CAR T-cell approaches has summarized key data presented at the 63rd American Society of Hematology (ASH) Annual Meeting.

Review the video to claim AMA credit after completion of the brief Post-Test/Evaluation.

Michael Wang, MD
Endowed Professor
Department of Lymphoma/Myeloma,
Professor
Department of Stem Cell Transplantation and Cellular Therapy
University of Texas MD Anderson Cancer Center

*This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings of the 2021 American Society of Hematology Annual Meeting (ASH)

Please review the required information below (use scroll bar on the right) and then click the

"Access Activity"

button to access this activity.

INTRODUCTION

This accredited continuing education Clinical Clip provides a brief expert video commentary spotlighting hot topics on CAR T-Cell Therapy.

Launch Date: December 17, 2021
Release Date: December 17, 2021
Expiration Date: November 30, 2022

TARGET AUDIENCE

Community and hospital based oncologists and hematologist/oncologists and members of their multidisciplinary treatment teams.

OVERALL LEARNING OBJECTIVES

Upon completion of this enduring material, participants should be able to:

METHOD OF PARTICIPATION / HOW TO RECEIVE CREDIT

There are no fees for participating in and receiving credit for this activity.
Review the activity objectives and CME information.
Successfully complete the post-test ( accuracy).
Complete the CME evaluation.
The estimated time to complete this activity is hour.
Upon successful completion, a certificate will be emailed to you.

ACCREDITATION AND DESIGNATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Practice Point Communications. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material activity for a maximum of AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHYSICIAN ASSITANTS, NURSE PRACTIONERS, NURSES AND OTHER HEALTHCARE PROFESSIONALS
Physician Assistants (AAPA), Nurse Practitioners (AANP), and Nurses (ANCC) can count ACCME activities certified for AMA PRA Category 1 Credit™ for professional credit reporting purposes. All healthcare professionals, other than physicians, should inquire with their respective certifying or licensing boards to confirm.

MITIGATION OF CONFLICT OF INTEREST

The University of Cincinnati adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests) over the last 24-months. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Information regarding the new updated ACCME Standards for Integrity and Independence in Accredited Continuing Education can be found on the ACCME website.

DISCLOSURE OF RELATIONSHIPS WITH INELIGIBLE COMPANIES

The University is committed to providing its learners with high-quality CME activities that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. The University requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all relationships with ineligible companies within the last 24-months. All relevant relationships are thoroughly vetted and mitigated according to the ACCME and University’s policy. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence.

The faculty and planners reported the following financial relationships, or relationships to products or devices, they have with ineligible companies (commercial interests) related to the content of this CME activity.

DISCLOSURES

The speakers and planning committee members listed below have stated they have no relevant relationships to disclose.
Susan Tyler, Ph.D
Robert Ellis, MD
Heather Muskopf
Nirupama Mulherkar
Ashley Richardson
Martin Stevens

FACULTY DISCLOSURES

Michael Wang, MD
Consultant: AstraZeneca, Bayer, BeiGene, CSTone, DTRM Biopharam, Epizyme, Genentech, Innocare, Janssen, Juno, Kite Pharma, Loxo Oncology, Miltenyi Biomedicine GmbH, Oncternal, Pharmacyclics, VelosBio
Research Funding: Acerta Pharma, AstraZeneca, Beigene, BioInvent, Celgene, Genentech, Innocare, Janssen, Juno, Kite Pharma, Lilly, Loxo Oncology, Molecular Templates, Oncternal, Pharmacyclics, VelosBio
Honoraria: AstraZeneca, Acerta Pharma, Anticancer Association, BeiGene, BGICS, CAHON, Chinese Medical Association, Clinical Care Options, Dava Oncology, Epizyme, Eastern Virginia Medical School, Hebei Cancer Prevention Federation, Imedex, Janssen, Kite Pharma, LLC TS Oncology, Miltenyi Biomedicine GmbH, Moffit Cancer Center, Mumbai Hematology Group, Newbridge Pharmaceuticals, OMI, Pharmacyclics, Physician Education Resources, Scripps, The First Afflicted Hospital of Zhejiang University

DISCLAIMER

The opinions expressed during this activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati and Practice Point Communications. The information is presented for the purpose of advancing the attendees’ professional development.

PRIVACY POLICY

The University of Cincinnati and Practice Point Communications protect the privacy of personal and other information regarding participants and educational collaborators. The University of Cincinnati and Practice Point Communications will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The University of Cincinnati and Practice Point Communications maintain physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.

COPYRIGHT INFORMATION

Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software (“Materials”) found on the site subject to the following terms, conditions, and exceptions:

The Materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.

Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without prior written permission.

HARDWARE/SOFTWARE REQUIREMENTS

Computer:

Hardware: A minimum of 512MB of RAM and a Pentium IV CPU for Intel-based hardware & PowerPC G4 or above for MAC.
Graphics/Monitor: A color monitor capable of a minimum of 1024 x 768 pixel resolution.
Network: An Internet connection with 1Mbps available download & 256kbps bandwidth.

Software/Browser:

Windows 7 or above running Internet Explorer 10 or above.
MAC OSX 10.5 (Leopard) or above running Safari 6 or above, or any version of Chrome, Firefox or Opera published in the last two years.
A recent version of a Linux distribution or FreeBSD running Chrome v13, Opera 11.5, Firefox 5.0.1, or Epiphany 3.0.4 or above.

Mobile Device:

Any Apple iPad or iPad Mini running iOS 7.1 or above.
Android tablets such as the Kindle Fire or Samsung Galaxy S.

COMMERCIAL SUPPORT ACKNOWLEDGMENT

Supported by independent educational grants from Bristol Myers Squibb.

Share This Activity

From:
To:
Subject:	I'd like to recommend this activity on www.PracticePointCME.com
Message:

/cmetest.aspx?testid=

Supported by an independent educational grant from Bristol Myers Squibb

Launch Date: December 17, 2021
Release Date: December 17, 2021
Expiration Date: November 30, 2022

November 30, 2022

Mini Module

7287

ClinicalClips_WebBanner.ASH.TCell(1150).gif

Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.

Hematology-Oncology

PRACTICE POINT CME

PRACTICE POINT COMMUNICATIONS

THERAPEUTIC AREAS

RESOURCES